Cagrilintide: How an Amylin Analog Combined with Semaglutide Targets Obesity Through Dual Brain Pathways

This is a review article summarizing the pharmacology of cagrilintide and semaglutide, their mechanisms of action, and clinical trial results. The review examines amylin biology, GLP-1 receptor agonist pharmacology, and the rationale for combining these two peptide classes for obesity treatment.

Obesity affects over a billion people worldwide and has limited pharmacological treatment options between lifestyle changes and bariatric surgery. While GLP-1 drugs like semaglutide have been transformative, many patients don't achieve sufficient weight loss with single-agent therapy. The cagrilintide-semaglutide combination targets obesity's heterogeneous pathophysiology more comprehensively, potentially helping more patients achieve clinically meaningful weight loss.

The development of cagrilintide represents the next wave of peptide-based obesity treatment — moving from single-target to multi-target approaches. Just as cardiovascular medicine uses combination therapy to address multiple risk factors, obesity medicine is adopting the same principle with dual-peptide combinations. This approach acknowledges that obesity is not a single-mechanism disease, and the amylin-GLP-1 combination addresses both the biological drive to eat and the pleasure-seeking aspects of food consumption.

This review was published before large-scale phase 3 trial results were available for the combination therapy. Long-term safety and efficacy data beyond trial durations are not available. Whether the combination's benefits outweigh additional costs and potential side effects compared to semaglutide alone is not fully established. The additive effects described may not translate to proportionally greater weight loss in all patient populations. Injection burden increases with combination therapy.